Rein Therapeutics (RNTX) Research & Development (2016 - 2026)
Rein Therapeutics (RNTX) posted quarterly Research & Development of $3.1 million for Q1 2026, up 0.62% year-over-year from $3.1 million in Q1 2025, and up 53.57% quarter-over-quarter from $2.0 million in Q4 2025.
Rein Therapeutics (RNTX) Research & Development (2016 - 2026) Analysis & Trends
Rein Therapeutics (RNTX) has reported Research & Development for 11 consecutive years, with $3.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development rose 0.62% year-over-year to $3.1 million; the TTM figure through Mar 2026 stood at $11.0 million (down 20.17% YoY), while the FY2025 annual figure was $11.0 million, down 22.59% from the prior year.
- Research & Development advanced to $3.1 million in Q1 2026 per RNTX's latest filing, from $2.0 million in the prior quarter.
- Across five years, Research & Development topped out at $5.9 million in Q1 2022 and bottomed at $22000.0 in Q3 2023.
- Historically, Research & Development has averaged $3.0 million across 5 years, with a median of $3.1 million in 2026.
- Annual changes were most pronounced in 2023 — Research & Development slumped 99.48% — and 2024, when it soared 16818.18%.
- Rein Therapeutics' Research & Development stood at $2.4 million in 2022, then dropped by 17.9% to $2.0 million in 2023, then soared by 68.46% to $3.3 million in 2024, then sank by 39.77% to $2.0 million in 2025, then soared by 53.57% to $3.1 million in 2026.
- Business Quant data shows RNTX's Research & Development at $3.1 million in Q1 2026, $2.0 million in Q4 2025, and $1.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Rein Therapeutics | 53.14 Mn | 53.14 Mn | - | 3.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.64 Mn |
| Mar 31, 2026 | 3.07 Mn |
| Dec 31, 2025 | 2.00 Mn |
| Sep 30, 2025 | 1.68 Mn |
| Jun 30, 2025 | 4.29 Mn |
| Mar 31, 2025 | 3.05 Mn |
| Dec 31, 2024 | 3.32 Mn |
| Sep 30, 2024 | 3.72 Mn |
| Jun 30, 2024 | 3.74 Mn |
| Mar 31, 2024 | 3.46 Mn |
| Dec 31, 2023 | 1.97 Mn |
| Sep 30, 2023 | 22,000.00 |
| Jun 30, 2023 | 187,000.00 |
| Mar 31, 2023 | 1.81 Mn |
| Dec 31, 2022 | 2.40 Mn |
| Sep 30, 2022 | 4.24 Mn |
| Jun 30, 2022 | 5.43 Mn |
| Mar 31, 2022 | 5.89 Mn |
| Dec 31, 2021 | 4.56 Mn |
| Sep 30, 2021 | 4.28 Mn |